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Antimicrobial Resistant Gram-positive Cocci  in Pregnant Mothers with Aerobic Vaginitis
The vaginal microbiota of a healthy asymptomatic woman consists of
an extensive diversity of anaerobic and aerobic bacterial genera and
species dominated by the microaerophilic genus Lactobacillus (Donati
et al., 2010), known to inhibit the growth of potentially pathogenic non-
acid tolerant microorganisms (Mijac et al., 2006; Li et al., 2011;
Stojanovic et al., 2012). An imbalance of species within this biofilm
may result in endogenous opportunistic infections such as aerobic
vaginitis (AV). Streptococcus agalactiae (S. agalactiae) and
Enterococcus faecalis (E. faecalis) were found to be the predominant
Gram-positive cocci in AV and have been implicated in neonatal and
obstetric sepsis. The prevalence and antibiotic profiles of bacteria
appear to differ in different geographical locations thus complicating
the standardisation of infection control.
The aim of the study was to determine the prevalence and
antimicrobial susceptibility of E. faecalis and S. agalactiae in pregnant
women with AV in the Western Cape, South Africa.
Figure 1. Frequency of S. agalactiae and E. faecalis in women with AV.
AV was detected in 52 of the 199 (26.13%) pregnant women, with S.
agalactiae and E. faecalis isolated from 32 and 20 mothers
respectively. Using EUCAST/CLSI breakpoints, S. agalactiae and E.
faecalis showed resistance to 12 of the 17 antibiotics tested, including
those recommended for prophylaxis according to the CDC guidelines,
namely penicillin, erythromycin, cefazolin, clindamycin, tetracycline
and vancomycin. Fig. 1 represents the number of women with S.
agalactiae and E. faecalis expressed as a percentage of the total
number of women with AV (N=79). The sensititre trek system results of
the antimicrobial susceptibility analysis for both S. agalactiae and E.
faecalis are shown in Table 1.
This study demonstrated the increasing resistance of S. agalactiae and
E. faecalis to the antimicrobials commonly administered for their
eradication and highlights the need for alternative treatment regimens for
AV during pregnancy to reduce the risk of (AV-associated) negative
pregnancy outcomes.
Ano-vaginal swab samples were collected from 301 women at 28-37
weeks of gestation. Patient demography was obtained by completion of
a questionnaire. The “AV” score was microscopically graded as absent,
slight, moderate or severe by comparing the proportion of lactobacilli
with leukocytes, other vaginal microflora and parabasal epithelial cells.
Swabs were cultured by routine methods and antibiotic susceptibility
profiles were determined using the Sensititre TREK system. Isolation
and identification of Gram-positive cocci were achieved by conventional
methods. The study complied with the Declaration of Helsinki (2013).
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ANTIMICROBIAL
Current pregnancy outcomes
Frequency (%)
E. faecalis
isolates
(n = 20)
Frequency (%)
S. agalactiae
isolates
(n = 32)
AZITHROMYCIN a
Susceptible 4 (20.0%) 16 (50.0%)
Intermediate 1 (5.0%) -
Resistant 15 (75.0%) 16 (50.0%)
CEFOTAXIME a
Susceptible - 18 (56.25%)
Intermediate -
Resistant 20 (100.0%) 14 (43.75%)
CEFTRIAXONE a
Susceptible - 18 (56.25%)
Intermediate -
Resistant 20 (100.0%) 14 (43.75%)
CHLORAMPHENICOL a
Susceptible 17 (85.0%) 23 (71.9%)
Intermediate -
Resistant 3 (15.0%) 9 (28.1%)
CLINDAMYCIN a
Susceptible 2 (10.0%) 18 (56.25%)
Intermediate 5 (25.0%)
Resistant 13 (65.0%) 14 (43.75%)
DAPTOMYCIN a
Susceptible 3 (15.0%) 20 (62.5%)
Intermediate - -
Resistant 17 (85.0%) 12 (37.5%)
ERTAPENEM b
Susceptible - 19 (40.6%)
Intermediate - -
Resistant 20 (100.0%) 13 (40.6%)
ERYTHROMYCIN a
Susceptible 2 (10.0%) 16 (50.0%)
Intermediate 1 (5.0%) -
Resistant 17 (85.0%) 16 (50.0%)
LEVOFLOXACIN a
Susceptible 12 (60.0%) 24 (75.0%)
Intermediate 2 (10.0%) 8 (25.0%)
Resistant 6 (30.0%) -
LINEZOLID a
Susceptible 17 (85.0%) 32 (100.0%)
Intermediate 2 (10.0%) -
Resistant 1 (5.0%)
MEROPENEM a
Susceptible 1 (5.0%) 19 (59.4%)
Intermediate - -
Resistant 19 (95.0%) 13 (40.6%)
MOXIFLOXACIN b
Susceptible 17 (85.0%) 30 (93.8%)
Intermediate - 1 (3.1%)
Resistant 3 (15.0%) 1 (3.1%)
TETRACYCLINE a
Susceptible 3 (15.0%) 3 (9.4%)
Intermediate - -
Resistant 17 (85.0%) 29 (90.6%)
TIGECYCLINE a
Susceptible 18 (90.0%) 32 (100.0%)
Intermediate 1 (5.0%) -
Resistant 1(5.0%) -
PENICILLIN a
Susceptible 1 (5.0%) 15 (46.9%)
Intermediate - -
Resistant 19 (95.0%) 17 (53.1%)
TRIMETHOPRIM/ 
SULPHAMETHOXAZOLE a
Susceptible 17 (85.0%) 31 (96.9%)
Intermediate - -
Resistant 3 (15.0%) 1 (3.1%) 
VANCOMYCIN a
Susceptible 15 (75.0%) 21 (65.6%)
Intermediate - -
Resistant 5 (25.0%) 11 (34.4%)
Table 1: Prevalence and susceptibility of E. faecalis  and S. 
agalactiae isolates in pregnant mothers with AV.
a CLSI breakpoint values were used. 
b EUCAST breakpoint values were used. 
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